Rash due to ipilimumab in patients with metastatic melanoma. (A) Generalized erythema, erythematous macules and papules. (B) Generalized erythema, erythematous macules, erythematous and some heme-crusted papules, and exfoliative scale on upper extremities in patient with high-grade rash. (C) Maculopapular exanthema.
Reproduced from:
Minkis K, Garden BC, Wu S, et al. The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis. J Am Acad Dermatol 2013; 69:e121. Illustration used with the permission of Elsevier Inc. All rights reserved.
Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 2014; 71:161. Illustration used with the permission of Elsevier Inc. All rights reserved.